Phaseline

Companies › Tangram Therapeutics

Tangram Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TGM-148–Phase 1Healthy ParticipantsMar 2028
TGM-312-SC01–Phase 1Healthy ParticipantsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07427680TGM-312-SC01Phase 1Healthy ParticipantsMetabolic and endocrineMar 2028
NCT07843368TGM-148Phase 1Healthy ParticipantsOtherMar 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.